373 related articles for article (PubMed ID: 32449439)
1. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
2. The value of improving the productivity of the drug development process: faster times and better decisions.
DiMasi JA
Pharmacoeconomics; 2002; 20 Suppl 3():1-10. PubMed ID: 12457421
[TBL] [Abstract][Full Text] [Related]
3. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
4. Use of benchmarking in the development of biopharmaceutical products.
Giffin M; McLeish S
Biotechnol Annu Rev; 2003; 9():279-84. PubMed ID: 14650932
[TBL] [Abstract][Full Text] [Related]
5. Japan-Specific Key Regulatory Aspects for Development of New Biopharmaceutical Drug Products.
Desai KG; Obayashi H; Colandene JD; Nesta DP
J Pharm Sci; 2018 Jul; 107(7):1773-1786. PubMed ID: 29601839
[TBL] [Abstract][Full Text] [Related]
6. [The long path (s) of placing medicines on the market].
Duguet C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
[No Abstract] [Full Text] [Related]
7. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs].
Giri I; Rouillon F
Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487
[No Abstract] [Full Text] [Related]
8. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
Garcia FA; Vandiver MW
PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
[TBL] [Abstract][Full Text] [Related]
9. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
Sahoo N; Manchikanti P
BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
[TBL] [Abstract][Full Text] [Related]
10. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
11. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
12. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
13. A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies.
Demmon S; Bhargava S; Ciolek D; Halley J; Jaya N; Joubert MK; Koepf E; Smith P; Trexler-Schmidt M; Tsai P
Biologicals; 2020 Sep; 67():9-20. PubMed ID: 32665104
[TBL] [Abstract][Full Text] [Related]
14. An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations.
Halley J; Chou YR; Cicchino C; Huang M; Sharma V; Tan NC; Thakkar S; Zhou LL; Al-Azzam W; Cornen S; Gauden M; Gu Z; Kar S; Lazar AC; Mehndiratta P; Smith J; Sosic Z; Weisbach P; Stokes ESE
J Pharm Sci; 2020 Jan; 109(1):6-21. PubMed ID: 31563512
[TBL] [Abstract][Full Text] [Related]
15. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Srai JS; Badman C; Krumme M; Futran M; Johnston C
J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
[TBL] [Abstract][Full Text] [Related]
16. NIIMBL-Facilitated Active Listening Meeting between Industry and FDA Identifies Common Challenges for Adoption of New Biopharmaceutical Manufacturing Technologies.
Mantle JL; Lee KH
PDA J Pharm Sci Technol; 2020; 74(5):497-508. PubMed ID: 32467179
[TBL] [Abstract][Full Text] [Related]
17. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
Zhuang Y; Chen D; Sharma A; Xu Z
AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
[TBL] [Abstract][Full Text] [Related]
18. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
[TBL] [Abstract][Full Text] [Related]
19. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
Grabowski H
Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
[TBL] [Abstract][Full Text] [Related]
20. Developments and opportunities in continuous biopharmaceutical manufacturing.
Khanal O; Lenhoff AM
MAbs; 2021; 13(1):1903664. PubMed ID: 33843449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]